Biocon Biologics gets EMA’s positive opinion for an ophthalmology product

Lonza delivers 5.6% CER sales growth and 30% CORE EBITDA margin

Good momentum in commercial CDMO business

Merck receives positive European Union CHMP opinion for Gefapixant

The CHMP’s recommendation will now be reviewed by the European Commission for marketing authorization in the European Union

Lupin launches Luforbec 100/6 for adult asthma and COPD treatment in Germany

Luforbec® 100/6 pMDI aims to provide comprehensive support to patients and healthcare professionals

Merck’s Phase 3 Keynote- A18 trial met PFS in patients with advanced cervical cancer

KEYTRUDA plus concurrent chemoradiotherapy demonstrated statistically significant and clinically meaningful improvement in PFS versus concurrent chemoradiotherapy alone in these patients

Tillotts Pharma and TVM Capital form Mage Biologics to develop oral antibody therapy for ulcerative colitis

Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis

Kintor Pharma completes first patient enrollment in long-term safety phase III trial of KX-826

The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023

Riparian Pharmaceuticals inks license and research agreement with Pfizer for cardiovascular programs

Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics

GE HealthCare expands partnership with TCS to transform IT operating model

This transformation will enable GE HealthCare to build a strong foundation for business growth

Briefs: Shivalik Rasayan and Dr. Reddy's Laboratories

Shivalik Rasayan Limited has issued LOA to Medicamen Biotech to use its DMF grade Bortezomib API for formulation of Bortezomib injection 3.5mg/ vial